Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

University of Colorado, Denver

Overview

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers

Ongoing study - results not available at this time

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Heroin Dependence Opioid-Related Disorders

Interventions

Opioid-Related DisordersDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use. Exclusion Criteria: Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Locations (1)

University of Colorado Health Sciences Center

Denver, Colorado, United States

Outcomes

Primary Outcomes

Subjective dose estimate

Observed withdrawal rating

Opioid agonist rating

Opioid antagonist rating

Pupil diameter

Analog rating scale for drug effects

Drug effect characteristics

Drug/Money Preferences

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.